Arbutus Biopharma Corp (ABUS)
3.46
+0.02
(+0.58%)
USD |
NASDAQ |
Nov 21, 16:00
3.46
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma Enterprise Value: 527.85M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 527.85M |
| November 20, 2024 | 524.06M |
| November 19, 2024 | 533.53M |
| November 18, 2024 | 539.22M |
| November 15, 2024 | 561.96M |
| November 14, 2024 | 560.06M |
| November 13, 2024 | 563.85M |
| November 12, 2024 | 561.96M |
| November 11, 2024 | 579.01M |
| November 08, 2024 | 582.80M |
| November 07, 2024 | 579.01M |
| November 06, 2024 | 615.01M |
| November 05, 2024 | 622.59M |
| November 04, 2024 | 605.54M |
| November 01, 2024 | 622.38M |
| October 31, 2024 | 600.60M |
| October 30, 2024 | 618.59M |
| October 29, 2024 | 637.54M |
| October 28, 2024 | 639.43M |
| October 25, 2024 | 624.28M |
| October 24, 2024 | 639.43M |
| October 23, 2024 | 641.32M |
| October 22, 2024 | 635.64M |
| October 21, 2024 | 643.22M |
| October 18, 2024 | 658.37M |
| Date | Value |
|---|---|
| October 17, 2024 | 652.69M |
| October 16, 2024 | 667.85M |
| October 15, 2024 | 650.80M |
| October 14, 2024 | 603.44M |
| October 11, 2024 | 607.23M |
| October 10, 2024 | 590.18M |
| October 09, 2024 | 584.49M |
| October 08, 2024 | 586.39M |
| October 07, 2024 | 578.81M |
| October 04, 2024 | 599.65M |
| October 03, 2024 | 601.54M |
| October 02, 2024 | 611.01M |
| October 01, 2024 | 597.75M |
| September 30, 2024 | 601.54M |
| September 27, 2024 | 581.05M |
| September 26, 2024 | 605.59M |
| September 25, 2024 | 596.15M |
| September 24, 2024 | 616.92M |
| September 23, 2024 | 620.69M |
| September 20, 2024 | 616.92M |
| September 19, 2024 | 639.57M |
| September 18, 2024 | 637.68M |
| September 17, 2024 | 628.24M |
| September 16, 2024 | 662.23M |
| September 13, 2024 | 701.87M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
119.19M
Minimum
Apr 03 2020
718.86M
Maximum
Sep 10 2024
319.98M
Average
292.38M
Median
Feb 14 2022
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 11.76B |
| Amicus Therapeutics Inc | 2.978B |
| Ionis Pharmaceuticals Inc | 4.154B |
| GlycoMimetics Inc | 6.243M |
| FibroGen Inc | 22.76M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.72M |
| Revenue (Quarterly) | 1.339M |
| Total Expenses (Quarterly) | 18.81M |
| EPS Diluted (Quarterly) | -0.10 |
| Profit Margin (Quarterly) | -1.47K% |
| Earnings Yield | -12.43% |
| Normalized Earnings Yield | -11.72 |